Breaking News

Sanofi, MyoKardia form partnership

Up to $200 million collaboration to develop targeted therapies for patients with genetic heart disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi and MyoKardia have formed a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia’s pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction. The collaboration, representing one of the largest research and development commitments to genetic for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters